期刊文献+

癌症爆发痛的现状和研究进展 被引量:7

Current research and advances in cancer breakthrough pain
原文传递
导出
摘要 虽然癌症患者的基础疼痛控制相当稳定,但也可能会遭受短暂的疼痛加重,即癌症爆发痛。典型的爆发痛有快速发作和持续时间短等临床特征,这种疼痛对患者生活质量和卫生资源的不良影响显而易见。即释型口服阿片类药物目前已广泛用于爆发痛的治疗,但其起效时间及作用持续时间长的特点并不适合治疗大部分的爆发痛。相比之下一些芬太尼制剂,如芬太尼透黏膜口含剂(oral transmucosal fentanyl citrate,OTFC)、芬太尼口腔泡腾片(fentanyl buccal tablet,FBT)、芬太尼舌下含片(sublingual fentanyl citrate,SLF)和芬太尼鼻喷雾剂(intranasal fentanyl spray,INFS)等,为癌症爆发痛的治疗带来了令人欣慰的疗效。另外,国内对布托啡诺鼻喷剂治疗癌症爆发痛也已有一定的研究。 Although the control of background pain is satisfying,the patients may also suffer from transient exacerbation of pain,which is known as cancer breakthrough pain(BTP).A typical episode of BTP has a fast onset and a short duration.The BTP can apparently affect the quality of life and may also have an adverse impact on healthcare resources.Normal-release oral opioids have been applied in the treatment of cancer BTP,but the late onset and long duration of action of oral opioids may not appropriate for controlling a typical cancer BTP.Some formulations of fentanyl provide more favourable efficacy in the control of cancer BTP,such as oral transmucosal fentanyl citrate(OTFC),buccal fentanyl citrate(FBT),sublingual fentanyl citrate(SLF),and intranasal fentanyl spray(INFS).In addition,some studies have focused on the treatment of cancer BTP with transnasal butorphanol.
作者 李华 刘巍
出处 《肿瘤》 CAS CSCD 北大核心 2011年第11期1046-1049,共4页 Tumor
关键词 肿瘤 爆发痛 类阿片 Neoplasms Breakthrough pain Opioids
  • 相关文献

参考文献28

  • 1HANKS G,HAWKINS C.Agreeing a gold standard in the management of cancer pain:the role of opioids[M].HILLIER R,FINLAY I,WELSH J,MILES A,editors.The effective management of cancer pain.UK Key Advances in Clinical Practice Series 2000.London:Aesculapius Medical Press,2000:57-77.
  • 2PORTENOY R,PAYNE D,JACOBSEN P.Breakthrough pain:characteristics and impact in patients with cancer pain[J].Pain,1999,81 (1-2):129-134.
  • 3PORTENOY R,HAGEN N.Breakthrough pain:definition,prevalence and characteristics[J].Pain,1990,41 (3):273-281.
  • 4CARACENI A,PORTENOY R K.An international survey of cancer pain characteristics and syndromes.IASP Task Force on Cancer Pain.International Association for the Study of Pain[J].Pain,1 999,82 (3):263-274.
  • 5DAVIES A N,DICKMAN A,REID C,et al.The management of cancer-related breakthrough pain:recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland[J].Eur J Pain,2009,13 (4):331-338.
  • 6PORTA-SALES J.Breakthrough cancer pain and current treatment options[J].Euro J Pain Suppl,2010,4 (3):181-185.
  • 7SIMMONDS M A.Management of breakthrough pain due to cancer[J].Oncology (Williston Park),1999,13 (8):1103-1108.
  • 8ZEPPETELLA G.Breakthrough pain in cancer patients[J].Clin Oncol (R Coll Radiol),2011,23 (6):393-398.
  • 9CARACENI A,MARTINI C,ZECCA E,et al.Breakthrough pain characteristics and syndromes in patients with cancer pain.An international survey[J].Palliat Med,2004,18 (3):177-183.
  • 10DAVIES A,ZEPPETELLA G,ANDERSEN S,et al.Multicentre European study of breakthrough cancer pain:Pain characteristics and patient perceptions of current and potential management strategies[J].Eur J Pain,2011,15(7):756-763.

二级参考文献11

  • 1黄宇光,罗爱伦.高级医师案头丛书,麻醉学[M].北京:中国协和医科大学出版社,2000:1—11
  • 2Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo - controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer [J]. Clin J Pain, 2006, 22(9) : 805 -811
  • 3Darwish M, Kirby M, Robertson P, Jr, et al. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics [ J ]. Clin Pharmacokinet, 2006, 45 ( 8 ) : 843 - 850
  • 4Darwish M, Kirby M, Robertson P Jr, et al. Pharmacokinetic properties of fentanyl effervescent buccal tablets : a phase Ⅰ, open - label, crossover study of single -dose 100,200,400, and 800 mierog in healthy adult volunteers[J]. Clin Ther, 2006, 28(5) : 707 -714
  • 5Darwish M, Tempero K, Kirby M, et al. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1080 pg versus oral transmucosal fentanyl citrate 1600 pg and dose proportionality of FEBT 270 to 1300 pg: A single -dose, randomized, open - label, three - period study in healthy adult volunteers [ J ]. Clin Ther, 2006, 28 (5) : 715 - 724
  • 6Darwish M, Kirby M, Robertson P Jr, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate [ J ]. J Clin Pharmacol, 2007, 47:343 -350
  • 7Fentra side effects [ OL/CD]. http: //drugs. com/sfx/fentora - side - effects. html
  • 8R.van Seventer et al.Comparison of TTS-fentanyl with sustained-release oral morphine inthe treatment of patients not using opioids for mild-to-moderate pain[].Current Medical Research and Opinion.2004
  • 9.
  • 10Jacox,A.,Carr,D.B.,Payne,R.New clinical-practice guidelines for the management of pain in patients with cancer[].The New England Journal of Medicine.1994

共引文献13

同被引文献55

  • 1国家药典委员会.中华人民共和国药典[M].北京:化学工业出版社,2005.114.
  • 2Middlemiss T, Laird BJ, Fallon MT. Mechanisms of cancer-induced bone pain[J]. Clinical Ontology, 2011, 23(6):387-392.
  • 3Leppert W, Buss T. The role of corticosteroids in the treatment of pain in cancer patients[J]. Curr Pain Headache Rep, 2012, 16(4):307-313.
  • 4Kim WM, Jeong CW, Lee SH, et al. The intrathecally administered kappa-2 opioid agonist GR89696 and interleukin-10 attenuate bone cancer- induced pain through synergistic interaction[J]. Anesth Analg, 2011, 113(4):934-940.
  • 5de Courcy JG. Interventional techniques for cancer pain management[J]. Clin Oncol (R Coil Radiol), 2011, 23(6):407-417.
  • 6Saghafi N, Lam DK, Schmidt BL. Cannabinoids attenuate cancer pain and proliferation in a mouse model[J]. Neurosci Lett, 2011,488(3):247-251.
  • 7Delaney A, Fleetwood-Walker SM, Colvin LA, et al. Translational medicine: cancer pain mechanisms and management[J]. Br J Anaesth, 2008, 101(1):87-94.
  • 8Paice JA. Chronic treatment-related pain in cancer survivors[J]. Pain, 2011, 152(3 Suppl):S84-89.
  • 9Lauretti GR, Rizzo CC, Mattos AL, et al, Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone[J]. Br J Cancer, 2013, 108(2):259-264.
  • 10NCCN指南中国版专家组.成人癌痛临床实践指南(中国版)[EB/OL].[2014-12-01].http://d.dxy.cn/preview/2095737.

引证文献7

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部